Immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles
Abstract Radiolabeled magnetic nanoparticles are promising candidates as dual-modality-contrast-agents (DMCA) for diagnostic applications. The immunocompatibility of a new DMCA is a prerequisite for subsequent in vivo applications. Here, a new DMCA, namely Fe3O4 nanoparticles radiolabeled with 68Ga,...
Enregistré dans:
Auteurs principaux: | Maria-Argyro Karageorgou, Dimosthenis Stamopoulos |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f9189ee69ced4cb9ba8b1377a0369d06 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Lipid-coated iron oxide nanoparticles for dual-modal imaging of hepatocellular carcinoma
par: Liang J, et autres
Publié: (2017) -
A Dual-Modality MR/PA Imaging Contrast Agent Based on Ultrasmall Biopolymer Nanoparticles for Orthotopic Hepatocellular Carcinoma Imaging
par: Sun J, et autres
Publié: (2019) -
Bombesin-functionalized superparamagnetic iron oxide nanoparticles for dual-modality MR/NIRFI in mouse models of breast cancer
par: Li L, et autres
Publié: (2019) -
Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents
par: Estelrich J, et autres
Publié: (2015) -
Assessment of Gold-Coated Iron Oxide Nanoparticles as Negative T2 Contrast Agent in Small Animal MRI Studies
par: Iancu SD, et autres
Publié: (2020)